Rigel raises 2025 revenue guidance to $285M-$290M as commercial sales growth accelerates
Source: SeekingAlpha
2025-11-04 20:07:15 ET
More on Rigel Pharmaceuticals
- Rigel Pharmaceuticals, Inc. (RIGL) Q3 2025 Earnings Call Transcript
- Rigel Pharmaceuticals: Strong Growth Trajectory And Commercial Expansion
- Rigel Pharmaceuticals: Q2 Earnings Fuel A Potential Breakout
- Rigel Pharmaceuticals GAAP EPS of $1.46 beats by $0.56, revenue of $69.46M beats by $7.58M
- Seeking Alpha’s Quant Rating on Rigel Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
Rigel raises 2025 revenue guidance to $285M–$290M as commercial sales growth accelerates
Rigel Pharmaceuticals Inc.
NASDAQ: RIGL
RIGL Trading
-5.14% G/L:
$26.58 Last:
27,381 Volume:
$27.01 Open:
RIGL Latest News
March 03, 2026 04:01:00 pm
Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
RIGL Stock Data
$625,132,287
16,430,597
0.07%
54
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
